Search clinical trials for: Buprenorphine + Rifampin

Total 972 results

University of Wisconsin, Madison
University of Wisconsin, Milwaukee

Completed

Treatment for Opioid Dependent Offenders

Opioid Dependence

United States
Braeburn Pharmaceuticals
Medpace, Inc.; Camurus AB

Completed

Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain (CAM2038)

Chronic Pain | Chronic Lower Back Pain

United States
University of Chicago

Completed

Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology (BED)

Depression

United States
Mundipharma (China) Pharmaceutical Co. Ltd

Completed

NORSPAN Transdermal Patches Phase III Study In Non-Cancer Pain

Disease (or Disorder); Intervertebral Disc, With Myelopathy (Manifestation)

China
Purdue Pharma LP

Completed

Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase

Osteoarthritis

United States
Emory University
National Institute on Drug Abuse (NIDA); Chestnut Health Systems

Withdrawn

Adolescent Community Reinforcement Approach in Combination With Buprenorphine/Naloxone for Severe Opioid Use (A-CRA/MAT)

Behavior, Addictive | Opioid-Related Disorders
Indivior Inc.

Completed

Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder

Opioid Use Disorder

United States
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)

Completed

Starting Treatment With Agonist Replacement Therapies (START)

Opiate-related Disorders

United States
University of California, Los Angeles

Not yet recruiting

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

Schizophrenia
Gangnam Severance Hospital

Completed

Transdermal Buprenorphine Patch for Laparoscopic Cholecystectomy

Laparoscopic Cholecystectomy

Korea, Republic of
New York State Psychiatric Institute

Completed

An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder

Opioid-use Disorder

United States
Purdue Pharma LP

Completed

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.

Back Pain

United States
Purdue Pharma LP

Terminated

Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.

Osteoarthritis

United States
Abarbanel Mental Health Center
Ministry of Health, Israel

Unknown

A Double-Blind Study of Buprenorphine Treatment of Acute Suicidality

Depression | Suicidal Ideation | Suicidal Action

Israel
Norwegian University of Science and Technology
St. Olavs Hospital; Alesund Hospital; Namsos Hospital; Volvat Medisinsk Senter...

Recruiting

Bariatric Surgery and Pharmacokinetics of Buprenorphine

Obesity, Morbid

Norway
Mundipharma AB

Completed

Norspan Efficacy and Safety Among Elderly Subjects

Osteoarthritis Pain of the Hip and or Knee

Sweden
National Institute on Drug Abuse (NIDA)
Beth Israel Medical Center

Unknown

Sublingual Buprenorphine for Chronic Pain

Chronic Pain

United States
BioDelivery Sciences International

Completed

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

Pain

United States
Oregon Health and Science University
Hanoi Medical University; Hennepin Healthcare Research Institute

Completed

Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO)

HIV | Substance Related Disorders

Vietnam
NYU Langone Health
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment

Opioid Use Disorder

United States
Pontificia Universidad Catolica de Chile
Sociedad Chilena de Pediatría

Unknown

Two Strategies of RDS Treatment in Newborns With Birth Weight > 1500 Grams

Respiratory Distress Syndrome

Chile
Janssen Research & Development, LLC

Recruiting

A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)

Arthritis, Juvenile

United States, France, Spain, United Kingdom, Turkey, Argentina, Germany, Italy, Poland, Denmark
Yale University
Harvard Medical School (HMS and HSDM); National Institute on Drug Abuse (NIDA) and other collaborators

Recruiting

Emergency Department-Initiated Buprenorphine Validation Network Trial

Opioid-use Disorder

United States
Indivior Inc.

Completed

SUBLOCADE Rapid Initiation Extension Study

Opioid Use Disorder, Moderate | Opioid Use Disorder, Severe

United States
University of Vermont Medical Center

Completed

Interim Buprenorphine: Leveraging Medication + Technology to Bridge Delays in Treatment Access (IBT)

Opioid-related Disorders

United States
Purdue Pharma LP

Completed

Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children

Pain

United States
Mundipharma K.K.

Completed

Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Low Back Pain

Low Back Pain

Japan
Grünenthal GmbH

Terminated

Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations

Healthy

Germany
Radboud University Medical Center

Recruiting

Pragmatic Optimized Rifampicin Trial (PORT)

Tuberculosis, Pulmonary

Netherlands
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Drug-drug Interaction Trial to Evaluate the Pharmacokinetics Effect of Rifampicin on Famitinib

Healthy Adult Subjects

China
Roxane Laboratories

Completed

Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions

Opioid-Related Disorders

United States
Purdue Pharma LP

Completed

Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
Purdue Pharma LP

Completed

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

Osteoarthritis

United States
Centre Hospitalier Universitaire, Amiens

Terminated

Surfactant Versus Nasal Continuous Positive Airway Pressure (nCPAP) for Respiratory Distress Syndrome in the Newborn ≥ 35 Weeks of Gestation (ASPEN)

Acute Respiratory Distress Syndrome

France
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Rifampicin on the Pharmacokinetics of Apatinib

Neoplasms

China
INSYS Therapeutics Inc

Terminated

Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

Post-operative Pain

United States
BioDelivery Sciences International

Withdrawn

The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects

Opioid Dependence

United States
Johns Hopkins University
National Institute on Drug Abuse (NIDA)

Completed

A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals

Opioid Dependence | Opioid Abuse

United States
Purdue Pharma LP

Completed

Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.

Chronic Pain

United States
Purdue Pharma LP

Completed

Safety of the Buprenorphine Transdermal Delivery System in Subjects With Mod-to-Sev Pain Following Orthopedic Surgery.

Postoperative Pain

United States
Lifespan
University of Rhode Island

Completed

Medication Maintenance Therapy in Community Pharmacy Settings (MATPharm)

Opioid-use Disorder

United States
Taiwan Mundipharma Pharmaceuticals Ltd.
Chang Gung Memorial Hospital; Taipei Medical University Shuang Ho Hospital; Changhua...

Completed

Safety and Effectiveness of Transdermal Buprenorphine in Cancer Pain (SOOTHE)

Cancer

Taiwan
St. Louis University

Completed

Buprenorphine Dose Adjustments and Gestational Age

Neonatal Abstinence Syndrome
Purdue Pharma LP

Completed

Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study

Chronic Nonmalignant Pain

United States
Purdue Pharma LP

Completed

Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods

Healthy

United States
NYU Langone Health
National Institute on Drug Abuse (NIDA)

Withdrawn

Assessing Optimal XR-Buprenorphine Initiation Points in Jail

Opioid Use Disorder

United States
Institute of Tropical Medicine, Belgium

Recruiting

Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (BE-PEOPLE P3)

Leprosy

Comoros
Turku University Hospital

Completed

Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine

Healthy

Finland
Astellas Pharma Global Development, Inc.
National Institute on Drug Abuse (NIDA)

Completed

A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder

Opioid Use Disorder

United States
PATH
London School of Hygiene and Tropical Medicine; Monash University; University... and other collaborators

Not yet recruiting

Assessing the Acceptability, Feasibility, Effectiveness and Cost-effectiveness of LADB

Opioid Dependence

Search clinical trials for: Buprenorphine + Rifampin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations